Table 1.
Demographic and baseline clinical features between PD patients with and without a positive ET history.
| Survival analysis (n = 785) | Motor and cognitive progression analysis (n = 704) | |||||||
|---|---|---|---|---|---|---|---|---|
| Unweighted sample | Weighted sample | Unweighted sample | Weighted sample | |||||
| With ET history (n = 61) | Without ET history (n = 724) | SMD | SMD | With ET history (n = 59) | Without ET history (n = 645) | SMD | SMD | |
| Education |
10.2 ± 3.9, 9 (3) |
10.0 ± 4.3, 9 (6) |
0.056 | 0.013 |
10.4 ± 3.7, 10 (4) |
10.1 ± 4.2, 9 (6) |
0.061 | 0.006 |
| BMI |
22.6 ± 2.6, 22.5 (3.6) |
23.1 ± 3.0, 22.9 (3.7) |
0.159 | 0.016 |
22.7 ± 2.6, 22.5 (3.6) |
23.1 ± 2.9, 22.9 (3.8) |
0.161 | 0.017 |
| Sex, male | 30 (49.2%) | 407 (56.2%) | 0.141 | 0.012 | 29 (49.2%) | 354 (54.9%) | 0.114 | 0.017 |
| Age |
58.3 ± 12.1, 57.8 (17.5) |
60.7 ± 11.8, 61.8 (17.0) |
0.198 | 0.012 |
58.0 ± 12.0, 57.8 (17.3) |
59.3 ± 11.2, 60.4 (16.8) |
0.107 | 0.012 |
| Age of onset |
56.7 ± 12.1, 56.5 (16.6) |
59.1 ± 11.8, 60.2 (17.2) |
0.198 | 0.012 |
56.4 ± 12.0, 56.5 (16.8) |
57.7 ± 11.2, 59.1 (16.9) |
0.113 | 0.012 |
| Disease duration |
1.6 ± 0.9, 1.3 (1.4) |
1.6 ± 0.8, 1.6 (1.4) |
0.001 | 0.001 |
1.7 ± 0.9, 1.3 (1.4) |
1.6 ± 0.8, 1.5 (1.4) |
0.091 | 0.003 |
| LEDD |
174.3 ± 208.7, 0 (325) |
204.4 ± 210.4, 150 (350) |
0.144 | 0.021 |
169.4 ± 202.0, 0 (325) |
203.9 ± 211.5, 150 (350) |
0.167 | 0.013 |
| Levodopa | 27 (44.3%) | 378 (52.2%) | 0.117 | 0.021 | 26 (44.1%) | 329 (51.0%) | 0.139 | 0.018 |
| Dopamine agonist | 14 (23.0%) | 205 (28.3%) | 0.160 | 0.001 | 13 (22.0%) | 190 (29.5%) | 0.170 | 0.009 |
| UPDRS III |
21.1 ± 10.9, 22 (17) |
24.7 ± 12.3, 24 (17) |
0.313 | 0.026 |
21.2 ± 11.0, 23 (17) |
23.2 ± 11.4, 23 (16) |
0.181 | 0.033 |
| Motor subtypes, TD/Intermediate/PIGD | 48/6/7 | 281/83/360 | 0.957 | 0.005 | 47/6/6 | 265/75/305 | 0.937 | 0.001 |
| H&Y stage |
1.8 ± 0.6, 2.0 (0.5) |
1.9 ± 0.6, 2.0 (0) |
0.166 | 0.016 |
1.8 ± 0.6, 2.0 (0.5) |
1.9 ± 0.6, 2 (0.5) |
0.084 | 0.022 |
| FAB |
16.0 ± 2.0, 16 (2) |
15.7 ± 2.4, 16 (3) |
0.103 | 0.003 |
16.0 ± 1.9, 16 (2) |
15.9 ± 2.3, 17 (3) |
0.053 | 0.001 |
| MoCA |
24.9 ± 4.0, 26 (4) |
24.0 ± 4.4, 25 (6) |
0.217 | 0.021 |
25.2 ± 3.3, 26 (4) |
24.5 ± 4.0, 25 (5) |
0.187 | 0.016 |
| HDRS |
8.3 ± 7.5, 6 (10) |
9.1 ± 7.8, 7 (10) |
0.111 | 0.016 |
8.3 ± 7.4, 6 (10) |
9.1 ± 7.7, 7 (6) |
0.105 | 0.012 |
| HARS |
6.3 ± 5.8, 4 (7) |
6.6 ± 5.9, 5 (8) |
0.050 | 0.010 |
6.3 ± 5.8, 4 (7) |
6.6 ± 5.9, 5 (8) |
0.048 | 0.008 |
| NMSS |
26.3 ± 28.9, 14 (30) |
33.7 ± 28.7, 27 (34) |
0.257 | 0.016 |
25.4 ± 27.2, 14 (30) |
31.8 ± 27.4, 26 (33) |
0.235 | 0.013 |
PD: Parkinson’s disease. ET: Essential tremor. SMD: standardized mean differences. BMI: body mass index. LEDD: Levodopa Equivalent Daily Doses. UPDRS: Unified Parkinson’s disease Rating Scale. H&Y stage: Hoehn and Yahr stage. FAB: Frontal Assessment Battery. MoCA: Montreal Cognitive Assessment. HDRS: Hamilton Depression Rating Scale. HARS: Hamilton Anxiety Rating Scale. NMSS: Non-Motor Symptoms Scale.